

Weber David M  
Form 4  
August 01, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Weber David M

2. Issuer Name and Ticker or Trading Symbol  
ABIOMED INC [ABMD]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

\_\_\_ Director \_\_\_ 10% Owner  
\_X\_ Officer (give title below) \_\_\_ Other (specify below)

C/O ABIOMED, INC., 22 CHERRY HILL DRIVE

07/30/2018

Chief Operating Officer

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

DANVERS, MA 01923

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, \$.01 par value	07/30/2018		M <sup>(5)</sup>		11,000 <sup>(5)</sup>	A	\$ 22.44
Common Stock, \$.01 par value	07/30/2018		S <sup>(6)</sup>		400 <sup>(6)</sup>	D	\$ 352.1475 <sup>(7)</sup>
Common Stock, \$.01 par value	07/30/2018		S <sup>(6)</sup>		1,000 <sup>(6)</sup>	D	\$ 353.255 <sup>(8)</sup>

Edgar Filing: Weber David M - Form 4

Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	<u>2,087</u> <sub>(6)</sub>	D	\$ <u>354.1832</u> <sub>(9)</sub>	163,637	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	<u>2,400</u> <sub>(6)</sub>	D	\$ <u>355.1267</u> <sub>(10)</sub>	161,237	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	<u>4,794</u> <sub>(6)</sub>	D	\$ <u>356.2331</u> <sub>(11)</sub>	156,443	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	<u>4,001</u> <sub>(6)</sub>	D	\$ <u>357.0892</u> <sub>(12)</sub>	152,442	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	<u>1,200</u> <sub>(6)</sub>	D	\$ <u>358.1467</u> <sub>(13)</sub>	151,242	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	<u>1,500</u> <sub>(6)</sub>	D	\$ <u>359.056</u> <sub>(14)</sub>	149,742	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	400 <u>(6)</u>	D	\$ <u>360.3825</u> <sub>(15)</sub>	149,342	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	400 <u>(6)</u>	D	\$ <u>360.8525</u> <sub>(16)</sub>	148,942	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	100 <u>(6)</u>	D	\$ 362.64	148,842	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	400 <u>(6)</u>	D	\$ <u>363.05</u> <sub>(17)</sub>	148,442	D
Common Stock, \$01 par value	07/30/2018	S <sup>(6)</sup>	300 <u>(6)</u>	D	\$ <u>363.96</u> <sub>(18)</sub>	148,142	D
	07/30/2018	S <sup>(6)</sup>	100 <u>(6)</u>	D	\$ 365	148,042	D

Edgar Filing: Weber David M - Form 4

Common  
Stock,  
\$.01 par  
value

Common  
Stock,  
\$.01 par  
value

Common  
Stock,  
\$.01 par  
value

07/30/2018

S<sup>(6)</sup>

200 <sup>(6)</sup>

D

\$ 365.91

147,842

D

15,497

I

By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Stock Option (right to buy) <sup>(2)</sup>	\$ 22.44	07/30/2018		M <sup>(5)</sup>	11,000 <sup>(5)</sup>	05/22/2013 <sup>(1)</sup> 05/22/2022	Common Stock	11,000
Stock Option (Right to Buy) <sup>(2)</sup>	\$ 23.15					05/14/2014 <sup>(1)</sup> 05/14/2023	Common Stock	0
Stock Option (Right to Buy) <sup>(2)</sup>	\$ 21.55					05/14/2015 <sup>(3)</sup> 05/14/2024	Common Stock	0
Stock Option (right to	\$ 66.25					05/13/2016 <sup>(3)</sup> 05/13/2025	Common Stock	0

buy) <sup>(2)</sup>					
Stock Option (right to buy) <sup>(4)</sup>	\$ 99.62	05/24/2017 <sup>(3)</sup>	05/24/2026	Common Stock	0
Stock Option (right to buy) <sup>(4)</sup>	\$ 134.51	05/15/2018 <sup>(3)</sup>	05/15/2027	Common Stock	0
Stock Option (right to buy) <sup>(4)</sup>	\$ 381.97	05/16/2019 <sup>(3)</sup>	05/16/2028	Common Stock	0

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Weber David M C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923			Chief Operating Officer	

## Signatures

/s/ Stephen C. McEvoy (by power of attorney) 08/01/2018

<sup>\_\_</sup>Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- (2) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- (3) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- (4) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- (5) Exercise of stock options pursuant to reporting owners 10b5-1 plan.
- (6) Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- (7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$351.6600 and \$352.5100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$352.7300 and \$353.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

## Edgar Filing: Weber David M - Form 4

- (9) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$353.7800 and \$354.5300. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (10) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$354.7400 and \$355.6300. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (11) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$355.7500 and \$356.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (12) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$356.6700 and \$357.5900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (13) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$357.6800 and \$358.5200. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (14) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$358.6900 and \$359.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (15) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$359.7300 and \$360.6400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (16) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$360.7200 and \$361.0100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (17) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$362.7500 and \$363.500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (18) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$363.7200 and \$364.3100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.